Browsing by Author "Kun, Chen"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Tea Consumption and Health Beneficences of Green Tea Drinking- A Community-based Cross-sectional Study in Urban Chinese Men.(2013-10) Chaowei, Fu; Jianxiang, Liu; Rongsheng, Luan; Kun, Chen; Hongqiang, Wang; Li, Liu; Biao, XuAims: To understand the exposure experiences of tea consumption in community male adult population of urban China and its potential beneficences in cardiovascular diseases and diabetes. Study Design: A cross-sectional study. Place and Duration of Study: Communities in Shanghai, Chengdu and Hangzhou, China between July to September, 2006. Methodology: Face-to-face questionnaire interviews through household visit were carried out to collect information on tea consumption and health conditions in Chinese men. The amount of tea-leaves consumed per time was weighed in grams using identical balances. Results: In this study, 73.7% (2156/2927) subjects met the criteria of present tea drinkers (PTDRs) at the time of interview, and the age-gender standardized proportion was 66.4%. Most of PTDRs drank tea every day and amounts of tea consumption did not vary over seasons. The average weekly amounts of tea consumption in grams for PTDRs varied from 55.2 grams green tea per week to 71.7 grams oolong tea per week. Also, green tea drinking was significantly inversely associated with cardiovascular disease and diabetes. Conclusion: This study provides an informative and comprehensive description of tea drinking in urban Chinese male population. Findings from this study also present the possibility of health benefits of green tea for male Chinese population.Item Tumor shrinkage rate as a potential marker for the prediction of long-term outcome in advanced non-small cell lung cancer treated with first-line tyrosine kinase inhibitors(Wolters Kluwer India Pvt. Ltd., 2020-01) Yu, Shanshan; Wang, Xingchen; Wang, Xiaoyan; Wu, Xueyuan; Xu, Rongrong; Wang, Xiaoqi; Xue, Zhang; Chunhong, Zhang; Kun, Chen; Cheng, Dezhi; Li, WenfengContext: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) play an indispensable role in the treatment of non-small cell lung cancer (NSCLC), leading to a survival major breakthrough, but there remains no uniform standard for predicting the efficacy of TKI therapy. Aims: We retrospectively reviewed the use of EGFR-TKIs for advanced NSCLC between January 2009 and December 2017 in a hospital, which 169 patients who treated with first-line TKIs were enrolled. Subjects and Methods: Multiple clinical factors, including histology, age, and sex, were analyzed. We calculated the tumor shrinkage rate (TSR) by measuring the longest diameters of the main mass by computed tomography (CT) before TKI therapy and the first CT after TKI therapy. We evaluated overall survival (OS) and progression-free survival (PFS) after first-line TKI therapy, and we assessed factors predicting survival using the Kaplan–Meier method. Results: Eligible patients were sorted into higher (n = 83) and lower (n = 86) TSR groups according to the mean TSR of 0.49%. The 83 patients with a higher TSR had longer PFS and OS than those in the 86 patients with a lower TSR (14.83 vs. 8.40 months, P < 0.001, and 31.03 vs. 20.10 months, P < 0.001, respectively). Multivariate analyses revealed that TSR was an independent predictor of PFS and OS (PFS hazard ratio [HR]: 0.506, P < 0.001, and OS HR: 0.291, P < 0.001). Conclusions: These cumulative data support that TSR may be an early predictor of the treatment efficacy in NSCLC with EGFR mutations treated with first-line TKIs